XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Revenue of XBiotech Inc. (XBIT)
Revenue in 2023 (TTM): $
According to XBiotech Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of XBiotech Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-1,744,000 | $-35,766,000 | $-24,313,000 | $-24,557,000 |
| 2022 | $4.01 M | $3.36 M | $-29,076,000 | $-33,588,000 | $-32,900,000 |
| 2021 | $18.39 M | $12.57 M | $-21,723,000 | $-25,458,000 | $-17,414,000 |
| 2020 | $44 M | $9.45 M | $-19,534,000 | $-12,827,000 | $-11,221,000 |
| 2019 | $ | $-2,361,000 | $-27,984,000 | $718.45 M | $668.63 M |
| 2018 | $ | $-2,433,000 | $-18,013,000 | $-21,138,000 | $-21,138,000 |
| 2017 | $ | $-1,484,000 | $-33,130,000 | $-33,150,000 | $-33,150,000 |
| 2016 | $ | $-698,000 | $-52,018,000 | $-52,761,000 | $-52,761,000 |
| 2015 | $ | $-699,000 | $-36,817,000 | $-37,483,000 | $-37,483,000 |
| 2014 | $ | $ | $-21,167,000 | $-21,724,000 | $-21,724,000 |
| 2013 | $ | $ | $-9,138,000 | $-9,927,000 | $-9,927,000 |
| 2012 | $ | $ | $-14,217,000 | $-15,160,000 | $-15,160,000 |